NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug.
The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in a significant way compared to a control therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post NantCell takes on troubled CytRx chemotherapeutic appeared first on MassDevice.
from MassDevice http://ift.tt/2vb8HiH
Cap comentari:
Publica un comentari a l'entrada